

Rick A Vreman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3389767/publications.pdf>

Version: 2024-02-01

25
papers

369
citations

1040056

9
h-index

888059

17
g-index

25
all docs

25
docs citations

25
times ranked

276
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding innovation of health technology assessment methods: the IHTAM framework. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e16.	0.5	2
2	Addressing uncertainty in relative effectiveness assessments by HTA organizations. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e17.	0.5	3
3	Real World Data in Health Technology Assessment of Complex Health Technologies. <i>Frontiers in Pharmacology</i> , 2022, 13, 837302.	3.5	15
4	Reported Challenges in Health Technology Assessment of Complex Health Technologies. <i>Value in Health</i> , 2022, 25, 992-1001.	0.3	9
5	Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 9, 76-84.	3.0	3
6	Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Value in Health</i> , 2021, 24, 121-128.	0.3	6
7	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e83.	0.5	10
8	Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00742.	2.4	9
9	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. <i>Clinical and Translational Science</i> , 2021, 14, 1566-1577.	3.1	10
10	Early Cost-Effectiveness of Onasemnogene Apeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. <i>Value in Health</i> , 2021, 24, 759-769.	0.3	24
11	Comment on "Deterministic Sensitivity Analysis Under Ignorance". <i>Pharmacoeconomics</i> , 2021, 39, 1199-1199.	3.3	0
12	The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. <i>Pharmacoeconomics</i> , 2021, 39, 1-17.	3.3	21
13	Getting the Right Evidence After Drug Approval. <i>Frontiers in Pharmacology</i> , 2020, 11, 569535.	3.5	10
14	Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8309.	2.6	20
15	Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. <i>Drug Discovery Today</i> , 2020, 25, 1223-1231.	6.4	11
16	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 350-357.	4.7	41
17	A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. <i>European Journal of Health Economics</i> , 2020, 21, 845-853.	2.8	1
18	Efficacy gap between phase II and subsequent phase III studies in oncology. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1306-1313.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. <i>Value in Health</i> , 2020, 23, 10-16.	0.3	37
20	Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 54.	1.5	2
21	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.9	8
22	Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 883-893.	2.1	15
23	Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions. <i>Value in Health</i> , 2019, 22, 1275-1282.	0.3	65
24	Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 684-691.	4.7	34
25	Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. <i>Pharmacogenomics</i> , 2017, 18, 1143-1153.	1.3	5